- Home
- TSVT vs ATOS Comparison
TSVT vs ATOS Comparison
Compare TSVT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- ATOS
- Stock Information
- Founded
- TSVT 2021
- ATOS 2009
- Country
- TSVT United States
- ATOS United States
- Employees
- TSVT N/A
- ATOS N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- ATOS Health Care
- Exchange
- TSVT Nasdaq
- ATOS Nasdaq
- Market Cap
- TSVT 128.5M
- ATOS 113.7M
- IPO Year
- TSVT N/A
- ATOS 2012
- Fundamental
- Price
- TSVT $2.45
- ATOS $0.87
- Analyst Decision
- TSVT Buy
- ATOS Strong Buy
- Analyst Count
- TSVT 6
- ATOS 3
- Target Price
- TSVT $10.40
- ATOS $7.00
- AVG Volume (30 Days)
- TSVT 449.7K
- ATOS 826.7K
- Earning Date
- TSVT 03-04-2025
- ATOS 11-12-2024
- Dividend Yield
- TSVT N/A
- ATOS N/A
- EPS Growth
- TSVT N/A
- ATOS N/A
- EPS
- TSVT N/A
- ATOS N/A
- Revenue
- TSVT $45,620,000.00
- ATOS N/A
- Revenue This Year
- TSVT N/A
- ATOS N/A
- Revenue Next Year
- TSVT $36.09
- ATOS N/A
- P/E Ratio
- TSVT N/A
- ATOS N/A
- Revenue Growth
- TSVT N/A
- ATOS N/A
- 52 Week Low
- TSVT $2.35
- ATOS $0.77
- 52 Week High
- TSVT $6.40
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- TSVT 35.00
- ATOS 34.91
- Support Level
- TSVT $2.36
- ATOS $0.91
- Resistance Level
- TSVT $2.53
- ATOS $0.94
- Average True Range (ATR)
- TSVT 0.18
- ATOS 0.06
- MACD
- TSVT 0.01
- ATOS 0.00
- Stochastic Oscillator
- TSVT 13.82
- ATOS 24.67
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.